The role of radiolabeled somatostatin analogs in adrenal imaging

Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours

“…Another study has also demonstrated an inhibitory effect of somatostatin in chromaffin cell cultures 46 . In vivo studies with radiolabelled somatostatin analogues, such as [ 111 In]‐octreotide, demonstrated that benign PHEOs were detectable in < 30% of cases 47,48 . However, recent studies have reported that sensitivity increased in malignant PHEOs 48,49 .…”

68Ga-DOTATATE PET in neuroectodermal tumours: First experience

“…These include, 6-[ 18 F]fluorodopamine, 11 C-hydroxyephedrine, 11 C-epinephrine, and 11 C-phenylephrine [23][24][25][26][27][28][29]. With these agents tumour visualization may be achieved several minutes after administration of the tracer.…”

“…Imaging with somatostatin analogues such as 111 Inoctreotide appears to be more sensitive in the detection of metastatic rather than benign phaeochromocytomas [10,11]. Several studies looking at 123 I-MIBG negative metastases have found imaging with somatostatin analogues to be complementary to that of 123 I-MIBG scanning [12][13][14][15][16][17].…”

Advanced Adrenal Imaging: Comparison between Radionuclide and MR Techniques

“…Several diagnostic methods, such as biological fluid tests, molecular markers, imaging techniques, and genome studies, have been proposed to differentiate between benign and malignant Pheo [44,45]. Previous data suggested that radiolabeled somatostatin analogs might be used to characterize malignant Pheo [18,46]. On the other hand, MIBG uptake has been demonstrated to reflect the concentration of neurosecretory storage granules in chromaffin tissue tumours [47].…”